Subscribe
designer491
designer491 / iStockphoto.com
31 May 2018Asia-Pacific

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Astellas boosts ocular pipeline with gene therapy acquisition
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Americas
Astellas accuses Cipla of infringing overactive bladder patent
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Asia-Pacific
Astellas boosts ocular pipeline with gene therapy acquisition
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Americas
Astellas accuses Cipla of infringing overactive bladder patent
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.

More on this story

Asia-Pacific
Astellas boosts ocular pipeline with gene therapy acquisition
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Americas
Astellas accuses Cipla of infringing overactive bladder patent
7 June 2018   Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler